D
Charles River Laboratories International, Inc. CRL
$175.92 $6.653.93%
Recommendation
Sell
Prev Close
$169.27
Volume
562
Avg Vol (90D)
928,696
Market Cap
$8.66B
Dividend & Yield
--
52-Week Range
$150.79 - $275.00
P/E (TTM)
1,115.82
EPS (TTM)
$0.1517
My Lists My Alerts
Rating
Reward
D+
Weak
Risk
D-
Weak
Rating Factors
Growth Index
Weak
Efficiency Index
Fair
Solvency Index
Excellent
Total Return Index
Weak
Volatility Index
Weak
Dividend Index
--
Headlines
Edgestream Partners L.P. Purchases New Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)
3/10/2025 - MarketBeat
Charles Schwab Investment Management Inc. Increases Stake in Charles River Laboratories International, Inc. (NYSE:CRL)
3/10/2025 - MarketBeat
E Fund Management Co. Ltd. Invests $336,000 in Charles River Laboratories International, Inc. (NYSE:CRL)
3/9/2025 - MarketBeat
Atria Investments Inc Trims Position in Charles River Laboratories International, Inc. (NYSE:CRL)
3/9/2025 - MarketBeat
Charles River Laboratories International (CRL, $175.92) price may drop as it broke higher Bollinger Band on Mar 07, 2025
3/8/2025 - Tickeron - Stocks
Victory Capital Management Inc. Has $60.17 Million Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)
3/8/2025 - MarketBeat
US Bancorp DE Lowers Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)
3/8/2025 - MarketBeat
Geneva Capital Management LLC Sells 2,026 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)
3/7/2025 - Ticker Report
Geneva Capital Management LLC Sells 2,026 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)
3/7/2025 - MarketBeat
Cullen Frost Bankers Inc. Sells 2,391 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)
3/7/2025 - MarketBeat
Spotting Winners: Charles River Laboratories (NYSE:CRL) And Drug Development Inputs & Services Stocks In Q4
3/5/2025 - StockStory Articles
Charles River Laboratories International (NYSE:CRL) Rating Increased to Neutral at Citigroup
3/4/2025 - Ticker Report
Charles River Laboratories International (NYSE:CRL) Rating Increased to Neutral at Citigroup
3/4/2025 - MarketBeat
Middleby Moves Up In Market Cap Rank, Passing Charles River Laboratories International
3/3/2025 - The Online Investor
Redburn Atlantic Upgrades Charles River Laboratories International (NYSE:CRL) to Neutral
3/3/2025 - Ticker Report
Redburn Atlantic Upgrades Charles River Laboratories International (NYSE:CRL) to Neutral
3/3/2025 - MarketBeat
Woodley Farra Manion Portfolio Management Inc. Sells 232,588 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)
3/3/2025 - MarketBeat
Charles River Laboratories International, Inc. (NYSE:CRL) Stock Holdings Cut by Bank of New York Mellon Corp
3/3/2025 - Ticker Report
Proficio Capital Partners LLC Makes New $10.77 Million Investment in Charles River Laboratories International, Inc. (NYSE:CRL)
3/3/2025 - MarketBeat
Parkside Financial Bank & Trust Cuts Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)
3/2/2025 - Ticker Report
The volume for Charles River Laboratories International stock increased for four consecutive days, resulting in a record-breaking daily growth of 165% of the 65-Day Volume Moving Average
3/1/2025 - Tickeron - Technical Analysis
Oppenheimer Asset Management Inc. Sells 13,651 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)
3/1/2025 - MarketBeat
NewEdge Wealth LLC Decreases Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)
3/1/2025 - MarketBeat
Bell Global Equities Sold Charles River Laboratories International (CRL) Due To Its Potential For On-going Risk To Earnings
2/28/2025 - Insider Monkey
Lattice Semiconductor Larger Than S&P 500 Component Charles River Laboratories International
2/26/2025 - The Online Investor
Income Statement
Total Revenue (TTM)
$4.05B
EBITDA (TTM)
$892.30M
EBIT (TTM)
$539.96M
Net Income (TTM)
$22.20M
Balance Sheet
Total Assets (Q)
$7.53B
Total Debt (Q)
$2.78B
Total Liabilities (Q)
$4.02B
Book Value Per Share (Q)
$67.69
Cash Flow
Cash from Operations (TTM)
$734.58M
Cash from Investing (TTM)
-$245.09M
Cash from Financing (TTM)
-$550.93M
Net Change in Cash (TTM)
-$78.91M
Filings
Filing Date
Wednesday, February 19, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 5 and 9 (est)
Price History
Loading...
Beta
0.96
7-Day Total Return
4.74%
30-Day Total Return
5.43%
60-Day Total Return
-8.28%
90-Day Total Return
-3.73%
Year to Date Total Return
-3.68%
1-Year Total Return
-34.91%
2-Year Total Return
-20.44%
3-Year Total Return
-33.98%
5-Year Total Return
23.18%
52-week Low
Feb 12, 2025 - $150.79
52-week High
Mar 08, 2024 - $275.00
Valuation
Market Cap
$8.66B - Mid Cap
Enterprise Value
$11.29B
Price/Sales (TTM)
2.14
Price/Book (Q)
2.50
Dividends and Shares
Shares Outstanding
51.14M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.criver.com
Phone Number
781 222 6000
Address
251 Ballardvale Street
Wilmington, MA 01887
Country
United States
Year Founded
1947
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and... more
NYSE 03/07/2025 3:00PM Eastern Quotes delayed
Weiss Ratings